Porwal Prateek Kumar, Dubey K P, Morey Amit, Singh Harshita, Pooja S, Bose Alokendu
Department of ENT, Tata Main Hospital, Bistupur, Jamshedpur, 831001 India.
Indian J Otolaryngol Head Neck Surg. 2018 Mar;70(1):145-148. doi: 10.1007/s12070-017-1243-x. Epub 2018 Jan 8.
The aim of this study is to evaluate the role of bleomycin as a primary mode of nonsurgical treatment in lymphangiomas of head and neck and study their complications. This is a prospective study of 8 patients diagnosed with lymphangioma of head and neck presenting to ENT department of Tata main Hospital from December 2014 to January 2017. They were clinically and radiologically evaluated and treated with intralesional injection of bleomycin diluted in normal saline. Complete resolution was seen in 62.5% (5/8) of patients, 25% (2/8) had good response while 12.5% (1/8) had a poor response. No major complications were noted apart from fever and inflammation. Intralesional bleomycin can be used as a primary modality of treatment.
本研究的目的是评估博来霉素作为头颈部淋巴管瘤非手术治疗主要方式的作用，并研究其并发症。这是一项对2014年12月至2017年1月在塔塔主医院耳鼻喉科就诊的8例诊断为头颈部淋巴管瘤患者的前瞻性研究。对他们进行了临床和放射学评估，并采用在生理盐水中稀释的博来霉素进行瘤内注射治疗。62.5%（5/8）的患者实现了完全消退，25%（2/8）有良好反应，而12.5%（1/8）反应较差。除发热和炎症外，未观察到重大并发症。瘤内注射博来霉素可作为主要治疗方式。
